AngioDynamics, Inc. earnings releases ANGO

AngioDynamics, Inc. last reported quarterly results on Oct 8, 2026, for Q1 FY2027 (the quarter ended Aug 31, 2026): revenue of $80.9 million (+6.9% year over year) and diluted EPS of -$0.17. It usually reports 33–44 days after a quarter ends. Based on that pattern, the next release is estimated for around Jan 5, 2027.

Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 33–44 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.

Released Quarter Revenue Net income Diluted EPS
Oct 8, 2026
38 days after quarter end
Q1 FY2027
ended Aug 31, 2026
81
+6.9%
-7
+34.9%
-0.17
+34.6%
Jul 14, 2026
44 days after quarter end
Q4 FY2026
ended May 31, 2026
87
+8.0%
-11
-88.5%
-0.27
-85.3%
Apr 2, 2026
33 days after quarter end
Q3 FY2026
ended Feb 28, 2026
78
+8.9%
-8
-83.4%
-0.19
-72.7%
Jan 6, 2026
37 days after quarter end
Q2 FY2026
ended Nov 30, 2025
79
+9.0%
-6
+40.9%
-0.15
+42.3%
Oct 2, 2025
32 days after quarter end
Q1 FY2026
ended Aug 31, 2025
76
+12.2%
-11
+14.8%
-0.26
+16.1%
Jul 15, 2025
45 days after quarter end
Q4 FY2025
ended May 31, 2025
80
+12.9%
-6
+55.0%
-0.15
+55.6%
Apr 2, 2025
33 days after quarter end
Q3 FY2025
ended Feb 28, 2025
72
-4.2%
-4
+97.7%
-0.11
+97.6%
Jan 8, 2025
39 days after quarter end
Q2 FY2025
ended Nov 30, 2024
73
-7.9%
-11
+63.0%
-0.26
+63.9%

Company profile

Industry
Surgical & Medical Instruments & Apparatus (SIC 3841)
Listed as
ANGO (Nasdaq)
Fiscal year ends
May 31
Incorporated in
DE
Headquarters
Latham, NY
SEC filer status
Accelerated filer
SEC CIK
1275187

Other Surgical & Medical Instruments & Apparatus companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.